Telix Plunges 10% After $2.35B ITM Deal — Dilution Panic or a Classic Value Hunt?

Podcast: Implied Podcast · Implied Podcast™

Opublikowano: 2026-10-21

Telix Pharmaceuticals just took a massive hit, dropping nearly 10% after announcing a $2.35 billion merger with ITM. While buying a top global supplier of therapeutic radioisotopes creates a vertically integrated powerhouse, the market completely freaked out over how Telix is paying for it: severe share dilution. With $1.25 billion of the upfront cost covered by issuing new shares, investors hated waking up to see their slice of the pie shrink overnight. In this episode, we break down whether this sell-off is a justified warning sign… or a rare, compelling entry point to buy into a fundamentally stronger company before the market di...